[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019005150A - Inhibidores de la tirosina-cinasa de bruton. - Google Patents

Inhibidores de la tirosina-cinasa de bruton.

Info

Publication number
MX2019005150A
MX2019005150A MX2019005150A MX2019005150A MX2019005150A MX 2019005150 A MX2019005150 A MX 2019005150A MX 2019005150 A MX2019005150 A MX 2019005150A MX 2019005150 A MX2019005150 A MX 2019005150A MX 2019005150 A MX2019005150 A MX 2019005150A
Authority
MX
Mexico
Prior art keywords
inhibitors
bruton
tyrosine kinase
irreversible
methods
Prior art date
Application number
MX2019005150A
Other languages
English (en)
Inventor
Wei Chen
Erik Verner
Lee Honigberg
Joseph J Buggy
David Loury
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/692,870 external-priority patent/US7732454B2/en
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2019005150A publication Critical patent/MX2019005150A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)

Abstract

En la presente se describen compuestos inhibidores de cinasa irreversibles, métodos para sintetizar dichos inhibidores irreversibles, y métodos para usar dichos inhibidores irreversibles en el tratamiento de enfermedades. En la presente se describen también métodos, ensayos y sistemas para determinar un inhibidor irreversible apropiado de una proteína, que incluye una cinasa.
MX2019005150A 2007-03-28 2009-09-24 Inhibidores de la tirosina-cinasa de bruton. MX2019005150A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/692,870 US7732454B2 (en) 2006-09-22 2007-03-28 Inhibitors of Bruton's tyrosine kinase
US11/964,285 US7825118B2 (en) 2006-09-22 2007-12-26 Inhibitors of bruton's tyrosine kinase
US1712507P 2007-12-27 2007-12-27

Publications (1)

Publication Number Publication Date
MX2019005150A true MX2019005150A (es) 2021-03-31

Family

ID=39808864

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009010284A MX2009010284A (es) 2007-03-28 2008-03-27 Inhibidores de la tirosina-cinasa de bruton.
MX2019005150A MX2019005150A (es) 2007-03-28 2009-09-24 Inhibidores de la tirosina-cinasa de bruton.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009010284A MX2009010284A (es) 2007-03-28 2008-03-27 Inhibidores de la tirosina-cinasa de bruton.

Country Status (14)

Country Link
EP (6) EP2543375A1 (es)
JP (2) JP5347202B2 (es)
KR (1) KR101425248B1 (es)
CN (2) CN103319488A (es)
AU (1) AU2008232762B2 (es)
BR (1) BRPI0810086B1 (es)
CA (4) CA2874756C (es)
EA (1) EA017865B1 (es)
ES (1) ES2562215T3 (es)
IL (8) IL295053A (es)
MX (2) MX2009010284A (es)
NZ (1) NZ579911A (es)
SG (2) SG10202107066WA (es)
WO (1) WO2008121742A2 (es)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ES2353437T3 (es) 2006-02-16 2011-03-02 Schering Corporation Derivados de pirrolidina como inhibidores de erk.
PT2526771T (pt) 2006-09-22 2017-02-27 Pharmacyclics Llc Inibidores de tirosina-cinase de bruton
EP2543375A1 (en) * 2007-03-28 2013-01-09 Pharmacyclics, Inc. Pyrrolo-pyrimidine analogues as inhibitors of bruton's tyrosine kinase
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
SG188179A1 (en) 2008-02-21 2013-03-28 Merck Sharp & Dohme Compounds that are erk inhibitors
JP5369183B2 (ja) 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
EP2789614B1 (en) 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
WO2011152351A1 (ja) 2010-05-31 2011-12-08 小野薬品工業株式会社 プリノン誘導体
AU2015275321B2 (en) * 2010-06-03 2018-03-15 Pharmacyclics Llc The use of inhibitors of Bruton's tyrosine kinase (Btk)
MX2020004438A (es) * 2010-06-03 2021-03-25 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2012255860C1 (en) * 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
SG194219A1 (en) * 2011-06-10 2013-11-29 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
AU2012275275A1 (en) * 2011-06-28 2014-01-23 Pharmacyclics Llc Methods and compositions for inhibition of bone resorption
ES2548414T3 (es) 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
JP2014522860A (ja) * 2011-07-19 2014-09-08 メルク・シャープ・アンド・ドーム・ベー・フェー Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
BR112014001255B1 (pt) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
RU2622391C2 (ru) * 2011-11-03 2017-06-15 Ф. Хоффманн-Ля Рош Аг Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона
MX353548B (es) * 2011-11-29 2018-01-18 Ono Pharmaceutical Co Clorhidrato derivado de purinona.
KR20130076046A (ko) * 2011-12-28 2013-07-08 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA2854093C (en) * 2012-01-19 2016-07-05 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2013118817A1 (ja) * 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
PL2722332T3 (pl) 2012-02-23 2016-10-31 Związek chinolilopirolopirymidylowy ze sprzężonym pierścieniem lub jego sól
WO2013133367A1 (ja) * 2012-03-09 2013-09-12 カルナバイオサイエンス株式会社 新規トリアジン誘導体
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
JP6175495B2 (ja) * 2012-05-31 2017-08-02 ファーマサイエンス・インコーポレイテッドＰｈａｒｍａｓｃｉｅｎｃｅ Ｉｎｃ． プロテインキナーゼ阻害薬
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
CA2782774A1 (en) 2012-07-06 2014-01-06 Pharmascience Inc. Protein kinase inhibitors
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
EP2882741B1 (en) 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
WO2014036016A1 (en) 2012-08-31 2014-03-06 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
ES2731833T3 (es) 2012-09-10 2019-11-19 Principia Biopharma Inc Compuestos pirazolopirimidínicos comos inhibidores de cinasas
BR112015011171A2 (pt) 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US9481682B2 (en) 2013-01-23 2016-11-01 Merck Sharp & Dohme Corp. Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
WO2014129596A1 (ja) 2013-02-22 2014-08-28 大鵬薬品工業株式会社 三環性化合物の製造方法及び当該製造方法により得ることができる三環性化合物
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EP2970163B1 (en) 2013-03-14 2018-02-28 Boehringer Ingelheim International GmbH 5-thiazolecarboxamide dervatives and their use as btk inhibitors
MY194905A (en) * 2013-03-15 2022-12-22 Janssen Pharmaceutica Nv Processes and Intermediates for Preparing a Medicament
WO2014152114A1 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
MX2015013685A (es) * 2013-04-02 2016-02-25 Hoffmann La Roche Inhibidores de tirosina cinasa de bruton.
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
JP6139782B2 (ja) * 2013-05-21 2017-05-31 チャンスー メドリューション リミテッド 置換ピラゾロピリミジン化合物、及びその薬学的に許容される塩、並びにこれらの溶媒和物、立体異性体、及び互変異性体、並びにこれらを含む医薬組成物
US9637487B2 (en) 2013-07-02 2017-05-02 Pharmacyclics Llc Purinone compounds as kinase inhibitors
JP6084292B2 (ja) * 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
TR201907147T4 (tr) 2013-07-18 2019-06-21 Taiho Pharmaceutical Co Ltd Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç.
WO2015017812A1 (en) 2013-08-02 2015-02-05 Pharmacyclics, Inc. Methods for the treatment of solid tumors
WO2015023703A1 (en) 2013-08-12 2015-02-19 Pharmacyclics, Inc. Methods for the treatment of her2 amplified cancer
DK2947086T3 (en) * 2013-08-12 2018-03-19 Taiho Pharmaceutical Co Ltd UNKNOWN CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF
MA38961A1 (fr) 2013-09-30 2018-05-31 Pharmacyclics Llc Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
RS60934B1 (sr) * 2013-09-30 2020-11-30 Guangzhou Innocare Pharma Tech Co Ltd Supstituisani nikotinimidni inhibitori btk i njihova priprema i upotreba u lečenju karcinoma, inflamatorne i autoimune bolesti
KR102671643B1 (ko) 2013-10-25 2024-05-31 파마싸이클릭스 엘엘씨 이식편 대 숙주 질환의 치료 및 예방 방법
CA2833867A1 (en) * 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
KR20160093062A (ko) 2013-12-05 2016-08-05 아세르타 파마. 비.브이. Pi3k 억제제 및 btk 억제제의 치료적 조합
WO2015095102A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015095099A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
EP3099674B1 (en) 2014-01-29 2018-10-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as btk inhibitors
BR112016016844A2 (pt) * 2014-02-03 2017-08-08 Cadila Healthcare Ltd Compostos heterocíclicos
EA033900B1 (ru) 2014-02-21 2019-12-06 Принсипиа Биофарма Инк. СОЛЕВЫЕ И АМОРФНЫЕ ФОРМЫ 2-[(3R)-3-[4-АМИНО-3-(2-ФТОР-4-ФЕНОКСИФЕНИЛ)ПИРАЗОЛО[3,4-d]ПИРИМИДИН-1-ИЛ]ПИПЕРИДИН-1-КАРБОНИЛ]-4-МЕТИЛ-4-[4-(ОКСЕТАН-3-ИЛ)ПИПЕРАЗИН-1-ИЛ]ПЕНТ-2-ЕННИТРИЛА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ПУЗЫРЧАТКИ ОБЫКНОВЕННОЙ И ПУЗЫРЧАТКИ ЛИСТОВИДНОЙ С ИХ ПРИМЕНЕНИЕМ
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US9416131B2 (en) 2014-03-25 2016-08-16 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN106458919B (zh) * 2014-05-13 2019-03-15 广东东阳光药业有限公司 一种中间体的制备方法
CN104086551B (zh) * 2014-06-06 2016-09-21 人福医药集团股份公司 化合物及其制备方法和用途
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
US9949971B2 (en) 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
KR102073797B1 (ko) * 2014-07-07 2020-02-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 단백질 키나제 저해제로서의 아미노피리다지논 화합물
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016022942A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
CN105461720B (zh) * 2014-08-08 2019-08-06 南京圣和药业股份有限公司 吗啉类酪氨酸激酶抑制剂
SI3179991T1 (sl) 2014-08-11 2022-04-29 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK in zaviralca BCL-2
CN107148421A (zh) * 2014-10-30 2017-09-08 桑多斯股份公司 活性丙烯酰胺类化合物
CN104407067B (zh) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 依鲁替尼及其异构体的检测方法
CN104447761A (zh) * 2014-11-27 2015-03-25 广东东阳光药业有限公司 一种吡唑衍生物的制备方法
ES2843323T3 (es) 2014-12-18 2021-07-16 Principia Biopharma Inc Tratamiento de pénfigo
CN105837576B (zh) * 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
MA41350A (fr) * 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
CN104557945B (zh) * 2015-01-27 2017-08-04 安润医药科技（苏州）有限公司 依鲁替尼合成方法
RU2712440C2 (ru) * 2015-02-12 2020-01-29 Шанхай Дьюд Медикал Сайенс Энд Текнолоджи Ко., Лтд Способ получения ибрутиниба
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
WO2016151438A1 (en) * 2015-03-20 2016-09-29 Sun Pharmaceutical Industries Limited A process for the preparation of ibrutinib
MA41828A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
MA41827A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
CN111393446B (zh) 2015-03-31 2022-12-20 大鹏药品工业株式会社 3,5-二取代的苯炔基化合物晶体
CN106146511A (zh) * 2015-04-03 2016-11-23 安润医药科技（苏州）有限公司 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
EP3281943B1 (en) 2015-04-09 2023-06-28 ONO Pharmaceutical Co., Ltd. Process for producing purinone derivative
CN106146512B (zh) * 2015-04-09 2018-07-17 北京睿创康泰医药研究院有限公司 依鲁替尼的制备方法
CN104844573A (zh) * 2015-04-17 2015-08-19 中国药科大学 嘧啶类btk抑制剂、其制备方法及医药用途
TW201718572A (zh) * 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
EP3317281B1 (en) 2015-07-02 2020-04-22 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
LV15201B (lv) 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts Ibrutiniba izejvielas iegūšanas paņēmiens
CA2997051C (en) 2015-09-01 2020-03-24 Taiho Pharmaceutical Co., Ltd. Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
KR20180109842A (ko) 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
EA035132B1 (ru) 2015-12-16 2020-04-30 Локсо Онколоджи, Инк. Соединения, которые можно применять в качестве ингибиторов киназы
AU2016370743B2 (en) 2015-12-16 2020-11-26 Boehringer Ingelheim International Gmbh Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
KR102688907B1 (ko) 2016-01-05 2024-07-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Btk 키나아제 억제제의 결정질 형태 및 이의 제조 방법
WO2017123695A1 (en) 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
CN106995446B (zh) * 2016-01-22 2021-07-02 山东新时代药业有限公司 布鲁顿酪氨酸激酶抑制剂制备方法
WO2017134588A1 (en) 2016-02-04 2017-08-10 Shilpa Medicare Limited Process for the preparation of ibrutinib
WO2017133630A1 (zh) * 2016-02-05 2017-08-10 北京盛诺基医药科技有限公司 一种布鲁顿酪氨酸激酶抑制剂
WO2017150725A1 (ja) 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US20190105407A1 (en) 2016-03-31 2019-04-11 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
CA3020918A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
AU2017268187A1 (en) 2016-05-20 2018-11-29 Eli Lilly And Company Combination therapy with notch and PD-1 or PD-L1 inhibitors
CN106083860A (zh) * 2016-06-23 2016-11-09 艾美科健（中国）生物医药有限公司 一种依鲁替尼中间体的合成与纯化工艺
MX2018016056A (es) 2016-06-29 2019-07-04 Principia Biopharma Inc Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo.
ES2878973T3 (es) * 2016-06-30 2021-11-19 Hangzhou Bangshun Pharmaceutical Co Ltd Derivado de fenilo de imidazopiridinamina y uso del mismo
CN108368119B (zh) * 2016-08-17 2019-04-23 深圳市塔吉瑞生物医药有限公司 用于抑制酪氨酸激酶活性的稠合双环类化合物
CN107759602B (zh) * 2016-08-17 2020-04-21 中国科学院上海药物研究所 含有共轭联烯结构的化合物、其药物组合物和用途
JP7201586B6 (ja) * 2016-09-08 2024-02-08 サビラ バイオサイエンシズ エルエルシー 神経保護作用、自己免疫性ならびに癌の疾患および病状において有用な１，２－ジチオラン化合物
EP3515414B1 (en) 2016-09-19 2022-11-30 MEI Pharma, Inc. Combination therapy
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
CN108069974B (zh) * 2016-11-15 2019-12-10 杭州和正医药有限公司 一种选择性布鲁顿酪氨酸激酶抑制剂及其应用
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
WO2018102785A2 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
CN106588937B (zh) 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
JP2020508326A (ja) 2017-02-24 2020-03-19 ギリアド サイエンシズ， インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
CA3054403A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
EP3601264A4 (en) 2017-03-22 2021-03-24 Xibin Liao INHIBITORS OF BRUTON TYROSIN KINASE
CN108727230B (zh) * 2017-04-21 2021-03-23 江苏希迪制药有限公司 依鲁替尼中间体及其制备方法
CN107043366B (zh) * 2017-04-25 2020-05-26 中国药科大学 4-氨基嘧啶类化合物、其制备方法及医药用途
CN109111446B (zh) * 2017-06-22 2021-11-30 上海度德医药科技有限公司 一种具有药物活性的杂芳基化合物
CN107602564B (zh) * 2017-09-20 2019-08-30 南京亘泰医药技术有限公司 布鲁顿酪氨酸激酶抑制剂
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
US11100492B2 (en) 2018-02-19 2021-08-24 Peter Garrett General purpose re-loadable card aggregation implementation
US11028088B2 (en) * 2018-03-10 2021-06-08 Yale University Modulators of BTK proteolysis and methods of use
KR102473372B1 (ko) 2018-03-19 2022-12-05 다이호야쿠힌고교 가부시키가이샤 알킬황산나트륨을 포함하는 의약 조성물
WO2019195753A1 (en) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Axl kinase inhibitors and use of the same
JP2021521170A (ja) 2018-04-13 2021-08-26 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤
JP7331843B2 (ja) 2018-04-27 2023-08-23 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
WO2020023910A1 (en) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
KR20210053304A (ko) 2018-08-29 2021-05-11 아세르타 파마. 비.브이. 4-｛8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일｝N-(피리딘-2-일)-벤즈아미드의 제조 공정
CN111440172B (zh) * 2019-01-17 2022-02-11 暨南大学 丙烯酰胺类化合物及其应用
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
JP2022520361A (ja) 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
CN114450289B (zh) * 2019-09-26 2024-01-02 成都嘉葆药银医药科技有限公司 作为选择性btk激酶抑制剂的吡唑并吡啶类化合物
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021180103A1 (en) * 2020-03-11 2021-09-16 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
AU2020436612A1 (en) * 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
US20230382900A1 (en) * 2020-10-30 2023-11-30 Newave Pharmaceutical Inc. Inhibitors of btk
CN112574216B (zh) * 2020-12-16 2022-03-08 天津济坤医药科技有限公司 一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用
CN113004246B (zh) * 2021-02-22 2022-02-01 广西医科大学 1，3，5-三嗪-2-胺-4，6取代衍生物或其药学上可接受的盐和用途
CN113402523B (zh) * 2021-07-13 2022-07-12 西安交通大学 一种靶向肥大细胞MrgX2小分子荧光探针及制备方法和应用
CN114195790B (zh) * 2021-11-18 2023-01-06 江苏阿尔法药业股份有限公司 一种依鲁替尼的合成方法
CN114276355B (zh) * 2022-01-26 2023-04-07 江苏阿尔法药业股份有限公司 一种依鲁替尼的制备方法
CN114605418B (zh) * 2022-03-15 2023-09-05 广东医科大学附属医院 一类具有抗肿瘤活性的依鲁替尼丙烯酰胺类衍生物及其合成方法与应用
WO2024097653A1 (en) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
WO1997049706A1 (en) * 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
EP0970084B1 (en) * 1997-03-19 2003-06-04 Basf Aktiengesellschaft Pyrrolo 2,3d]pyrimidines and their use as tyrosine kinase inhibitors
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6335155B1 (en) * 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6998233B2 (en) * 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US20050287596A9 (en) * 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
MXPA03008560A (es) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
EP2258371A1 (en) * 2001-08-10 2010-12-08 Novartis AG Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
EP1446496A4 (en) * 2001-11-21 2005-03-30 Sunesis Pharmaceuticals Inc METHODS OF DISCOVERING LIGANDS
US20050084905A1 (en) * 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) * 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
GB0303910D0 (en) * 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7687506B2 (en) * 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
EP1473039A1 (en) * 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
US7405295B2 (en) * 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
JP2005089352A (ja) * 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
AU2004282219C1 (en) * 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
ITMI20041314A1 (it) * 2004-06-30 2004-09-30 Nuvera Fuel Cells Europ Srl Dispositivo di raffreddamento per celle a combustibili a membrana
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
KR20070063562A (ko) * 2004-09-28 2007-06-19 얀센 파마슈티카 엔.브이. 치환 디피페리딘 ｃｃｒ２ 길항제
WO2006053121A2 (en) * 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
WO2006124462A2 (en) * 2005-05-13 2006-11-23 Irm, Llc Compounds and compositions as protein kinase inhibitors
MY147410A (en) * 2005-06-22 2012-11-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
RU2008133161A (ru) * 2006-01-13 2010-02-20 Фармасайкликс, Инк. (Us) Ингибиторы тирозин киназ и их применение
CA2858520A1 (en) * 2006-05-18 2007-11-29 Pharmacyclics Inc. Intracellular kinase inhibitors
PT2526771T (pt) * 2006-09-22 2017-02-27 Pharmacyclics Llc Inibidores de tirosina-cinase de bruton
US8987233B2 (en) * 2006-11-03 2015-03-24 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2543375A1 (en) * 2007-03-28 2013-01-09 Pharmacyclics, Inc. Pyrrolo-pyrimidine analogues as inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
EP2139487A2 (en) 2010-01-06
EP2139487B1 (en) 2015-11-11
IL295053A (en) 2022-09-01
CA3001152A1 (en) 2008-10-09
KR20100007864A (ko) 2010-01-22
EP2561875A3 (en) 2013-06-12
IL201176A0 (en) 2010-05-17
EA200901313A1 (ru) 2010-04-30
AU2008232762B2 (en) 2013-09-19
EP2543375A1 (en) 2013-01-09
JP2010526768A (ja) 2010-08-05
WO2008121742A2 (en) 2008-10-09
CA2681756C (en) 2015-02-24
CN103319488A (zh) 2013-09-25
SG10201508035TA (en) 2015-10-29
CA2874756C (en) 2018-05-29
EP2954900A1 (en) 2015-12-16
WO2008121742A3 (en) 2008-11-27
NZ579911A (en) 2012-05-25
ES2562215T3 (es) 2016-03-03
EP2560007A1 (en) 2013-02-20
IL239155A0 (en) 2015-07-30
BRPI0810086B1 (pt) 2021-11-09
CA2874756A1 (en) 2008-10-09
EP2561875A2 (en) 2013-02-27
CN101674834B (zh) 2013-06-12
IL280173A (en) 2021-03-01
JP5994051B2 (ja) 2016-09-21
EP2139487A4 (en) 2010-04-21
SG10202107066WA (en) 2021-07-29
KR101425248B1 (ko) 2014-08-06
AU2008232762A1 (en) 2008-10-09
CN101674834A (zh) 2010-03-17
IL239156A0 (en) 2015-07-30
EP2548558A1 (en) 2013-01-23
BRPI0810086A2 (pt) 2016-07-26
IL266741A (en) 2019-07-31
CA2681756A1 (en) 2008-10-09
CA3143428A1 (en) 2008-10-09
IL201176A (en) 2015-06-30
EA017865B1 (ru) 2013-03-29
JP2013253089A (ja) 2013-12-19
MX2009010284A (es) 2010-01-29
IL239154A0 (en) 2015-07-30
IL257017A (en) 2018-03-29
JP5347202B2 (ja) 2013-11-20

Similar Documents

Publication Publication Date Title
MX2009010284A (es) Inhibidores de la tirosina-cinasa de bruton.
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
AU2012283775A8 (en) Inhibitors of Bruton's tyrosine kinase
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
TW200801008A (en) Protein kinase inhibitors
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
CY2015016I2 (el) Αναστολεις της κινασης τυροσινης του bruton
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
UA99284C2 (ru) ИНГИБИТОРЫ р70 S6-КИНАЗЫ
MY153198A (en) Inhibitors of protein aggregation
HK1109059A1 (en) Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof
EA200801430A1 (ru) Производные триазола
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
NO20084190L (no) Anvendelse av VX-702 til behandling av revmatoid artritt
WO2006057997A3 (en) Plasmin-inhibitory therapies
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
ATE528561T1 (de) Inline-ventilpatrone
AU2013276959B2 (en) Inhibitors of Bruton's tyrosine kinase